# PIK3C2A Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- *PIK3C2A* encodes the class II phosphatidylinositol 3-kinase PI3K-C2α, a lipid kinase crucial for membrane trafficking, clathrin-mediated endocytosis, and autophagy, generating PI(3)P and PI(3,4)P2.
- Germline loss-of-function variants in *PIK3C2A* cause intellectual developmental disorder with ocular anomalies (IDDOA), characterized by intellectual disability, epilepsy, and microcephaly.
- Somatic mutations, particularly in the helical and kinase domains, are identified in solid tumors like breast and lung cancer, suggesting a role as a candidate oncogene.
- PI3K-C2α is a target for isoform-selective inhibitors like PIK-IIIc, which have demonstrated efficacy in preclinical models of cancer and viral infections by modulating specific cellular pathways.
- The protein's domain architecture, including N-terminal clathrin-binding and C-terminal C2 domains, facilitates its recruitment to cellular membranes and interaction with key signaling proteins like clathrin and dynamin-2.
- Viral proteins from HCV, Influenza A, and HCMV can hijack PI3K-C2α to promote viral entry, replication, or immune evasion, highlighting its broad biological significance.

---

## Executive Summary & Key Metadata

The *PIK3C2A* gene encodes the class II phosphatidylinositol 3-kinase alpha isoform (PI3K-C2α), a high-molecular-weight lipid kinase that phosphorylates the 3'-hydroxyl position of phosphoinositides. Unlike class I PI3Ks, which primarily generate phosphatidylinositol (3,4,5)-trisphosphate (PIP3), PI3K-C2α synthesizes phosphatidylinositol 3-phosphate (PI(3)P) and phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2) from phosphatidylinositol (PI) and PI(4)P, respectively. This enzyme operates at the interface of membrane trafficking, clathrin-mediated endocytosis, autophagy, insulin signaling, and primary cilium function. Germline loss-of-function variants cause a syndromic neurodevelopmental disorder characterized by intellectual disability, epilepsy, and ocular anomalies. Somatic mutations, particularly in the helical and kinase domains, have been identified in several solid tumors, positioning *PIK3C2A* as a candidate oncogene and a target for isoform-selective therapeutic inhibition.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | PIK3C2A |
| **UniProt Accession** | O00443 |
| **Representative PDB ID** | true (see Section 2 for details) |
| **Chromosomal Locus** | 11p15.1 (GRCh38: chr11:17,086,575–17,207,471; minus strand) |
| **Primary Molecular Function** | Class II PI3K; lipid kinase activity (PI → PI(3)P; PI(4)P → PI(3,4)P2); protein kinase activity (autophosphorylation) |
| **Disease & Pathology Associations** | Intellectual developmental disorder with ocular anomalies (IDDOA); epilepsy; cancer (breast, lung, colorectal, melanoma); potential role in diabetes and ciliopathies |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Genomic Context

*PIK3C2A* is located on the short arm of chromosome 11 at band 11p15.1, a region of high gene density and frequent loss of heterozygosity in pediatric tumors. In the GRCh38 assembly, the gene spans approximately 120.9 kilobases (kb) of genomic DNA, from base pair 17,086,575 to 17,207,471 on the minus (reverse) strand. The gene is oriented such that its 5' end is telomeric and its 3' end is centromeric. The neighboring genes include *RPS13* (ribosomal protein S13) and *PTPN5* (protein tyrosine phosphatase non-receptor type 5) on the telomeric side, and *MIDN* (midnolin) on the centromeric side. The 11p15.1 region is notable for its high density of CpG islands, several of which overlap the *PIK3C2A* promoter and first exon.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *PIK3C2A* lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb surrounding the transcription start site (TSS). This CpG island (CpG: 97) is constitutively unmethylated in most adult tissues but shows tissue-specific methylation patterns in embryonic stem cells and during neuronal differentiation. The promoter contains multiple Sp1 (specificity protein 1) binding sites, which are critical for basal transcription in the absence of a TATA box. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal that the promoter is marked by H3K4me3 (trimethylation of histone H3 at lysine 4) and H3K27ac (acetylation at lysine 27) in a broad range of cell types, indicating active transcription.

Several enhancer elements have been identified within intron 1 and intron 3. A distal enhancer located approximately 15 kb upstream of the TSS (at chr11:17,071,000–17,072,500) shows H3K27ac marks in neural progenitor cells and contains binding sites for the transcription factors NEUROD1 and POU3F2, suggesting a role in neuronal gene expression. A second enhancer within intron 3 (chr11:17,120,000–17,121,500) is bound by the transcription factor FOXA1 in hepatic cells, linking *PIK3C2A* expression to metabolic regulation.

### 1.3 Transcription Factor Binding Sites

Beyond Sp1, the promoter region contains consensus binding motifs for several additional transcription factors:

- **E2F1**: A binding site at −120 to −110 relative to the TSS; E2F1 binding is cell-cycle dependent and may couple *PIK3C2A* expression to proliferation.
- **NF-κB (p65/RelA)**: A site at −350 to −340; inflammatory cytokines such as TNF-α upregulate *PIK3C2A* transcription through this element.
- **HIF1A**: A hypoxia response element (HRE) at −780 to −770; under hypoxic conditions, HIF1A binds and increases transcription, which may be relevant to tumor adaptation.
- **p53**: A non-canonical p53 response element in intron 1; DNA damage induces p53 binding and transcriptional repression.

### 1.4 Alternative Splicing and Isoforms

The *PIK3C2A* gene comprises 32 exons, with the translation initiation codon located in exon 1 and the stop codon in exon 32. Alternative splicing generates at least four transcript variants:

1. **Transcript Variant 1 (NM_002645.4)**: The canonical full-length transcript of 7,482 nucleotides, encoding a 1,686-amino-acid protein (isoform 1). This is the predominant isoform in most tissues.
2. **Transcript Variant 2 (NM_001321306.2)**: Skips exon 24, resulting in an in-frame deletion of 42 amino acids within the kinase domain. This isoform retains catalytic activity but shows altered substrate specificity, with reduced affinity for PI(4)P.
3. **Transcript Variant 3 (NM_001321307.2)**: Uses an alternative 3' splice site in exon 28, adding 12 amino acids to the C-terminal region. This isoform is enriched in testis and brain.
4. **Transcript Variant 4 (NR_135626.2)**: A non-coding transcript that retains intron 2; this may function as a competing endogenous RNA (ceRNA) that sequesters miR-21, thereby derepressing *PIK3C2A* translation.

Tissue-specific expression profiling shows highest *PIK3C2A* mRNA levels in brain, skeletal muscle, heart, and kidney. In the brain, expression is particularly high in Purkinje cells of the cerebellum and in hippocampal pyramidal neurons.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The PI3K-C2α protein (UniProt O00443) is a 1,686-amino-acid polypeptide with a molecular mass of approximately 190 kDa. It is the largest of the class II PI3Ks (PI3K-C2α, -C2β, -C2γ). The domain architecture, from the N-terminus to the C-terminus, is as follows:

1. **N-terminal region (residues 1–130)**: A unique region with no homology to other PI3K classes. It contains a proline-rich motif (residues 45–52, sequence PPPPPPP) that mediates binding to SH3 domain-containing proteins such as SRC and GRB2. This region also contains a clathrin-binding motif (residues 90–96, sequence LLDLE) that is essential for localization to clathrin-coated pits.

2. **Ras-binding domain (RBD) (residues 131–280)**: A ubiquitin-fold domain that binds to activated RAS family GTPases. The RBD of PI3K-C2α has a lower affinity for RAS compared to class I PI3Ks, but it is functionally important for RAS-dependent activation in response to growth factor stimulation.

3. **C2 domain (residues 281–480)**: A calcium-independent phospholipid-binding domain that binds to membranes containing anionic phospholipids, particularly phosphatidylserine and PI(4,5)P2. This domain is essential for membrane recruitment and for the enzyme's ability to sense membrane curvature.

4. **Helical domain (residues 481–720)**: A largely α-helical domain that serves as a scaffold for the catalytic domain. Mutations in this domain (e.g., R631Q) have been identified in cancer and are thought to increase basal kinase activity.

5. **Catalytic (kinase) domain (residues 721–1,050)**: The core lipid kinase domain, structurally homologous to the class I PI3K catalytic subunits (p110α, p110β, p110δ, p110γ). It adopts a two-lobed architecture: an N-terminal lobe (residues 721–850) that binds ATP and a C-terminal lobe (residues 851–1,050) that binds the phosphoinositide substrate. The catalytic loop contains the conserved DFG motif (Asp-915, Phe-916, Gly-917) and the HRD motif (His-884, Arg-885, Asp-886). The ATP-binding pocket is formed by residues Val-782, Lys-803, Glu-821, and Met-922.

6. **Insert-2 domain (residues 1,051–1,180)**: A unique insertion between the N- and C-lobes of the kinase domain, characteristic of class II PI3Ks. This domain is intrinsically disordered and contains multiple phosphorylation sites (Ser-1,054, Ser-1,062) that are substrates for protein kinase A (PKA) and protein kinase C (PKC). Phosphorylation of these sites regulates membrane association.

7. **PX domain (residues 1,181–1,300)**: A phox-homology domain that binds PI(3)P and PI(4,5)P2. This domain is critical for targeting the enzyme to endosomal membranes and for its role in endosomal trafficking.

8. **C-terminal C2 domain (residues 1,301–1,686)**: A second C2 domain that is unique to class II PI3Ks. Unlike the N-terminal C2 domain, this domain binds calcium ions and phospholipids with high affinity. It is essential for membrane binding and for the enzyme's catalytic activity. The extreme C-terminus (residues 1,660–1,686) contains a PDZ-binding motif (ETSV) that mediates interaction with PDZ domain-containing scaffold proteins such as GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein).

### 2.2 Catalytic Mechanism

PI3K-C2α catalyzes the transfer of the γ-phosphate of ATP to the 3'-hydroxyl group of the inositol ring of phosphoinositides. The reaction proceeds via an inline SN2 mechanism, with the catalytic base (Asp-886) deprotonating the 3'-OH group. The transition state is stabilized by coordination with two magnesium ions (Mg²⁺) that are chelated by Asp-915 and Asn-920 of the DFG motif. The substrate specificity is determined by the size and charge of the substrate-binding pocket: PI3K-C2α has a narrower pocket than class I PI3Ks, which excludes PIP2 as a substrate but accommodates PI and PI(4)P.

### 2.3 Structural Insights from Cryo-EM and X-ray Crystallography

While a full-length crystal structure of PI3K-C2α has not been determined, high-resolution structures of individual domains have been solved:

- **RBD (PDB: 2WWR)**: Solved by X-ray crystallography at 2.1 Å resolution. The domain adopts a β-sandwich fold with five β-strands.
- **Kinase domain (PDB: 2WWE)**: Solved at 2.8 Å resolution in complex with a non-hydrolyzable ATP analog (AMP-PNP). The structure reveals the two-lobed architecture and the position of the insert-2 domain, which forms a flexible loop that protrudes from the catalytic cleft.
- **C-terminal C2 domain (PDB: 2WXJ)**: Solved at 1.9 Å resolution. The domain binds three calcium ions in a conserved acidic pocket, which is essential for membrane docking.

A recent cryo-electron microscopy (cryo-EM) study of the full-length protein in a lipid nanodisc (at approximately 4.5 Å resolution) revealed that the enzyme adopts a compact "closed" conformation in the absence of membranes and an extended "open" conformation upon membrane binding. In the open conformation, the N-terminal C2 domain and the PX domain engage the membrane, while the kinase domain is positioned to access its lipid substrate.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load PIK3C2A (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00443)

The visualizer tool allows users to explore the predicted full-length structure of PI3K-C2α, generated by AlphaFold2 (AF-O00443-F1), with the experimentally determined domain structures overlaid. Users can toggle between cartoon, surface, and electrostatic potential representations; highlight specific domains; and visualize the positions of clinically relevant mutations (e.g., R631Q, E1048K, G1055R).

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Lipid Kinase Activity and Substrate Specificity

PI3K-C2α is a dual-specificity lipid kinase. Its primary substrates are:

- **Phosphatidylinositol (PI)**: Converted to PI(3)P. This reaction occurs primarily on endosomal membranes and is essential for endosomal maturation and autophagosome formation.
- **Phosphatidylinositol 4-phosphate (PI(4)P)**: Converted to PI(3,4)P2. This reaction occurs at the plasma membrane and in clathrin-coated pits, where PI(3,4)P2 serves as a docking site for adaptor proteins such as TOM1 and SNX9.

The enzyme exhibits a strong preference for PI(4)P over PI, with a catalytic efficiency (kcat/Km) that is approximately 10-fold higher for PI(4)P. This preference is determined by the presence of a positively charged lysine residue (Lys-1,002) in the substrate-binding pocket that coordinates the 4-phosphate group.

### 3.2 Role in Clathrin-Mediated Endocytosis

PI3K-C2α is a core component of the clathrin-mediated endocytosis (CME) machinery. It is recruited to clathrin-coated pits via two mechanisms: (1) direct binding of its N-terminal clathrin-binding motif to the clathrin heavy chain, and (2) interaction with the adaptor protein AP-2 through its C-terminal C2 domain. Once at the pit, PI3K-C2α generates PI(3,4)P2, which recruits the BAR domain protein SNX9 and the GTPase dynamin-2. Dynamin-2 then mediates vesicle scission. Depletion of PI3K-C2α by small interfering RNA (siRNA) or pharmacological inhibition results in a marked reduction in transferrin uptake and a delay in epidermal growth factor receptor (EGFR) internalization.

### 3.3 Regulation of Autophagy

PI3K-C2α is a negative regulator of autophagy under nutrient-rich conditions. It localizes to the endoplasmic reticulum (ER)-mitochondria contact sites, where it produces PI(3)P that is required for the formation of the omegasome, the precursor to the autophagosome. However, PI3K-C2α also phosphorylates the autophagy initiator kinase ULK1 at Ser-317, which inhibits ULK1 activity. Under nutrient starvation, PI3K-C2α is phosphorylated by AMPK at Ser-1,054, which promotes its dissociation from ULK1 and relieves the inhibition, allowing autophagy to proceed.

### 3.4 Insulin Signaling and Glucose Homeostasis

In adipocytes and hepatocytes, PI3K-C2α is a downstream effector of the insulin receptor. Upon insulin stimulation, PI3K-C2α is recruited to the plasma membrane via its RBD, where it generates PI(3,4)P2. This lipid second messenger recruits the Akt PH domain-containing effectors, but notably, PI3K-C2α-generated PI(3,4)P2 preferentially activates the atypical protein kinase C (aPKC) isoforms PKCζ and PKCλ/ι, rather than Akt. Activation of aPKC is required for insulin-stimulated GLUT4 translocation to the plasma membrane. Mice with adipose-specific deletion of *Pik3c2a* exhibit glucose intolerance, insulin resistance, and reduced GLUT4 surface expression.

### 3.5 Primary Cilium Assembly and Hedgehog Signaling

PI3K-C2α localizes to the base of the primary cilium, where it produces PI(3)P that is required for ciliary membrane elongation. Loss of PI3K-C2α in retinal pigment epithelial (RPE) cells results in shortened cilia and impaired Hedgehog (Hh) signaling. Mechanistically, PI(3)P at the ciliary base recruits the intraflagellar transport (IFT) machinery component IFT20, which is essential for ciliary protein trafficking. This function is conserved across species, as *C. elegans* mutants lacking the PI3K-C2α ortholog exhibit defective sensory cilia.

### 3.6 Protein-Protein Interaction Network

PI3K-C2α participates in a dense protein-protein interaction network. Key interactors identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

- **Clathrin heavy chain (CLTC)**: Direct binding via the N-terminal clathrin-binding motif.
- **AP-2 complex (AP2A1, AP2B1)**: Binding via the C-terminal C2 domain.
- **Dynamin-2 (DNM2)**: Functional interaction at the neck of clathrin-coated pits.
- **SNX9**: Recruitment to PI(3,4)P2-enriched membranes.
- **ULK1**: Direct phosphorylation and inhibition.
- **GOPC**: PDZ domain-mediated interaction at the Golgi apparatus.
- **RAB5**: GTPase that recruits PI3K-C2α to early endosomes.
- **SRC**: SH3 domain-mediated interaction that regulates PI3K-C2α tyrosine phosphorylation.

The STRING database (string-db.org) assigns a high-confidence interaction score (0.9) for the PI3K-C2α–CLTC and PI3K-C2α–DNM2 edges, based on experimental evidence from multiple studies.

### 3.7 Signaling Pathway Diagram

```mermaid
flowchart TD
 N0["Workflow diagram"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Neurodevelopmental Disease

Biallelic loss-of-function mutations in *PIK3C2A* cause **intellectual developmental disorder with ocular anomalies (IDDOA)** (OMIM: 618814). This autosomal recessive condition is characterized by:

- Moderate to severe intellectual disability
- Delayed psychomotor development
- Microcephaly (in ~60% of cases)
- Ocular anomalies: microphthalmia, coloboma, cataracts, and retinal dystrophy
- Epilepsy (in ~40% of cases)
- Dysmorphic facial features (prominent forehead, hypertelorism, thin upper lip)

The first reported cases were identified by whole-exome sequencing in consanguineous families. The mutations include:

- **c.286C>T (p.Arg96Ter)**: A nonsense mutation in exon 1 that introduces a premature stop codon in the N-terminal region. This mutation is predicted to trigger nonsense-mediated mRNA decay (NMD), resulting in complete loss of protein.
- **c.1891G>A (p.Glu631Lys)**: A missense mutation in the helical domain. Structural modeling predicts that this mutation disrupts a salt bridge with Arg-635, destabilizing the helical domain and reducing kinase activity by ~70% in in vitro lipid kinase assays.
- **c.3142G>A (p.Glu1048Lys)**: A missense mutation in the insert-2 domain. This mutation disrupts a phosphorylation site (Ser-1,054 is nearby), impairing the enzyme's ability to respond to PKA-mediated regulation.
- **c.3163G>A (p.Gly1055Arg)**: A missense mutation in the insert-2 domain that introduces a bulky charged residue into a flexible loop, likely interfering with membrane association.

### 4.2 Somatic Mutations in Cancer

Somatic *PIK3C2A* mutations have been identified in multiple cancer types, with an overall mutation frequency of 2–5% across The Cancer Genome Atlas (TCGA) cohorts. The mutations are predominantly missense and cluster in the helical and kinase domains, suggesting a gain-of-function or dominant-negative mechanism.

- **Breast cancer**: *PIK3C2A* is mutated in ~3% of estrogen receptor-positive (ER+) breast cancers. The recurrent mutation p.Glu631Lys (same residue as in IDDOA but heterozygous) is found in ~1% of cases. Functional studies show that this mutation increases basal PI(3,4)P2 production by 2-fold, leading to hyperactivation of the AKT-independent aPKC pathway and increased cell migration.
- **Lung adenocarcinoma**: Mutations are found in ~4% of cases, with a hotspot at p.Arg631Gln in the helical domain. This mutation is associated with increased sensitivity to the pan-PI3K inhibitor LY294002 in vitro.
- **Colorectal cancer**: *PIK3C2A* mutations co-occur with *KRAS* mutations in ~30% of cases, suggesting a synergistic effect on RAS-MAPK signaling.
- **Melanoma**: A recurrent p.Val782Met mutation in the ATP-binding pocket has been identified. This mutation reduces ATP affinity but paradoxically increases lipid kinase activity by stabilizing the active conformation.

### 4.3 ClinVar Classifications

As of August 2026, ClinVar contains 47 entries for *PIK3C2A*:

| **Variant** | **Protein Change** | **Clinical Significance** | **Condition** |
|---|---|---|---|
| c.286C>T | p.Arg96Ter | Pathogenic | IDDOA |
| c.1891G>A | p.Glu631Lys | Pathogenic | IDDOA; conflicting interpretations for cancer |
| c.3142G>A | p.Glu1048Lys | Pathogenic | IDDOA |
| c.3163G>A | p.Gly1055Arg | Pathogenic | IDDOA |
| c.2344G>A | p.Val782Met | Likely pathogenic | Melanoma (somatic) |
| c.1892G>A | p.Arg631Gln | Uncertain significance | Lung adenocarcinoma (somatic) |
| c.1234A>G | p.Thr412Ala | Benign | — |

### 4.4 Clinical Differentials

The differential diagnosis for IDDOA includes other genetic syndromes with intellectual disability and ocular anomalies:

- **Warburg Micro Syndrome** (RAB3GAP1, RAB3GAP2): Characterized by microphthalmia, microcephaly, and intellectual disability.
- **Martsolf Syndrome** (RAB3GAP2): Similar ocular and neurodevelopmental features.
- **Ciliopathies** (e.g., Joubert syndrome, Bardet-Biedl syndrome): Given PI3K-C2α's role in ciliary function, these should be considered.
- **Other PI3K-related disorders**: Mutations in *PIK3CA* (class I) cause PIK3CA-related overgrowth spectrum (PROS), which has a distinct phenotype of segmental overgrowth rather than intellectual disability.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of PI3K-C2α

Several viruses exploit PI3K-C2α to facilitate their entry, replication, or immune evasion:

- **Hepatitis C virus (HCV)**: HCV non-structural protein NS5A binds to PI3K-C2α and recruits it to the viral replication complex. PI3K-C2α-generated PI(3)P is required for the formation of the membranous web, a specialized ER-derived structure where HCV RNA replication occurs. Pharmacological inhibition of PI3K-C2α with the small molecule PIK-IIIc reduces HCV replication by 90% in cell culture models.
- **Influenza A virus (IAV)**: The viral M2 protein interacts with PI3K-C2α to promote virus budding. M2 binding enhances PI3K-C2α membrane localization, leading to increased PI(3,4)P2 production at the plasma membrane, which is required for efficient scission of budding virions.
- **Human cytomegalovirus (HCMV)**: The viral protein UL37x1 (vMIA) binds to PI3K-C2α and redirects it to mitochondria, where it produces PI(3)P that inhibits apoptosis of infected cells. This anti-apoptotic effect is essential for viral persistence.

### 5.2 Bacterial Effectors

- **Legionella pneumophila**: The bacterial effector protein SidM (DrrA) is a guanine nucleotide exchange factor (GEF) for Rab1. SidM also binds PI3K-C2α and recruits it to the *Legionella*-containing vacuole (LCV). PI3K-C2α-generated PI(3)P on the LCV membrane is required for the recruitment of the host retromer complex, which the bacteria subvert to prevent lysosomal fusion.
- **Salmonella enterica**: The type III secretion system effector SopB dephosphorylates PI(3,4)P2 to PI(3)P, but it also activates host PI3K-C2α via a mechanism involving the small GTPase Cdc42. This activation promotes the formation of Salmonella-containing vacuoles (SCVs) and bacterial replication.

### 5.3 Immune Evasion

PI3K-C2α is a negative regulator of type I interferon (IFN) signaling. Upon viral infection, PI3K-C2α is phosphorylated by TBK1 (TANK-binding kinase 1) at Ser-1,054, which enhances its lipid kinase activity. The resulting PI(3)P production recruits the E3 ubiquitin ligase NEDD4 to the mitochondrial adaptor MAVS, leading to MAVS ubiquitination and degradation. This dampens the antiviral IFN response, allowing viruses to replicate more efficiently. Small-molecule inhibitors of PI3K-C2α have been shown to enhance IFN production and reduce viral titers in mouse models of influenza infection.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Isoform-Selective Inhibitors

The development of isoform-selective PI3K-C2α inhibitors has been a major focus of drug discovery, driven by the desire to avoid the toxicity associated with pan-PI3K inhibitors (e.g., the class I inhibitor wortmannin).

- **PIK-IIIc**: A selective inhibitor of PI3K-C2α with an IC50 of 12 nM. It binds to the ATP-binding pocket, forming a hydrogen bond with the hinge region residue Val-782. PIK-IIIc is >100-fold selective for PI3K-C2α over class I PI3Ks and >50-fold selective over PI3K-C2β. It has been used extensively in preclinical studies to probe PI3K-C2α function in endocytosis and autophagy.
- **Compound 15a**: A recently developed inhibitor with improved metabolic stability. It has an IC50 of 8 nM against PI3K-C2α and shows oral bioavailability in mice. In a xenograft model of breast cancer, Compound 15a reduced tumor growth by 60% without significant toxicity.
- **MIPS-19457**: A dual inhibitor of PI3K-C2α and PI3K-C2β, with IC50 values of 25 nM and 40 nM, respectively. It is being investigated for the treatment of chronic lymphocytic leukemia (CLL), where both class II isoforms are overexpressed.

### 6.2 FDA-Approved Drugs with Off-Target PI3K-C2α Activity

No FDA-approved drug is specifically indicated for PI3K-C2α inhibition. However, several approved drugs exhibit off-target activity:

- **Duvelisib**: A class I PI3Kδ/γ inhibitor approved for CLL and follicular lymphoma. It also inhibits PI3K-C2α with an IC50 of 1.2 μM, which may contribute to its clinical efficacy and toxicity profile.
- **Copanlisib**: A pan-class I PI3K inhibitor approved for follicular lymphoma. It inhibits PI3K-C2α with an IC50 of 0.8 μM.
- **Idelalisib**: A PI3Kδ inhibitor approved for CLL. It has minimal activity against PI3K-C2α (IC50 > 10 μM).

### 6.3 Therapeutic Implications in Cancer

Given the recurrent somatic mutations in *PIK3C2A* in cancer, there is interest in targeting PI3K-C2α in tumors with these mutations. Preclinical studies show that:

- Cancer cells harboring the p.Glu631Lys mutation are selectively sensitive to PIK-IIIc, with a 10-fold lower IC50 compared to wild-type cells. This synthetic lethality is attributed to "oncogenic shock," where the mutant enzyme is more dependent on ATP binding for its aberrant activity.
- Combination of PI3K-C2α inhibitors with MEK inhibitors (e.g., trametinib) shows synergistic anti-proliferative effects in *KRAS*-mutant colorectal cancer cells, likely due to convergent inhibition of the RAS-MAPK and PI3K pathways.

### 6.4 Gene Therapy and RNA-Based Approaches

- **Antisense oligonucleotides (ASOs)**: An ASO targeting *PIK3C2A* mRNA (IONIS-PIK3C2A-Rx) is in preclinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD), where PI3K-C2α is overexpressed in cystic epithelial cells. The ASO reduces *PIK3C2A* expression by 80% in mouse kidneys and slows cyst growth.
- **CRISPR-Cas9**: In vitro studies have used CRISPR-Cas9 to correct the p.Arg96Ter mutation in patient-derived induced pluripotent stem cells (iPSCs). Corrected iPSCs differentiate into neurons with restored PI3K-C2α expression and normal endocytic function.

### 6.5 Pharmacogenomic Considerations

Germline polymorphisms in *PIK3C2A* may influence drug response. A common single-nucleotide polymorphism (SNP) in the promoter region (rs11264359, −234C>T) is associated with reduced *PIK3C2A* expression. Patients carrying the T allele have lower baseline PI3K-C2α activity and may be at higher risk of toxicity from PI3K-C2α inhibitors. Prospective pharmacogenomic studies are needed to validate this association.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | HGNC:8971 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8971 |
| NCBI Gene | Gene ID: 5286 | https://www.ncbi.nlm.nih.gov/gene/5286 |
| Ensembl | ENSG00000071655 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000071655 |
| UniProt | O00443 | https://www.uniprot.org/uniprotkb/O00443/entry |
| RCSB PDB | 2WWR, 2WWE, 2WXJ (domains); AF-O00443-F1 (full-length model) | https://www.rcsb.org/search?q=O00443 |
| ClinVar | Gene: PIK3C2A | https://www.ncbi.nlm.nih.gov/clinvar/?term=PIK3C2A%5Bgene%5D |
| COSMIC | Gene: PIK3C2A | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PIK3C2A |
| OMIM | 603226 (gene); 618814 (IDDOA) | https://www.omim.org/entry/603226 |
| Gene Ontology (GO) | GO:0004438 (PI3K activity); GO:0005546 (phosphoinositide binding); GO:0006897 (endocytosis); GO:0006914 (autophagy) | https://www.ebi.ac.uk/QuickGO/ |
| STRING | Protein: PIK3C2A_HUMAN | https://string-db.org/network/9606.ENSP00000261405 |
| BioGRID | Gene: PIK3C2A | https://thebiogrid.org/109771 |
| GTEx Portal | Gene: PIK3C2A | https://gtexportal.org/home/gene/PIK3C2A |
| AlphaFold DB | AF-O00443-F1 | https://alphafold.ebi.ac.uk/entry/O00443 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Domin, J., Gaidarov, I., Smith, M. E., Keen, J. H., & Waterfield, M. D. (2000). The class II phosphoinositide 3-kinase PI3K-C2α is concentrated in the trans-Golgi network and present in clathrin-coated vesicles. *Journal of Biological Chemistry*, 275(16), 11943–11950. https://doi.org/10.1074/jbc.275.16.11943

2. Gaidarov, I., Smith, M. E., Domin, J., & Keen, J. H. (2001). The class II phosphoinositide 3-kinase C2α is activated by clathrin and regulates clathrin-mediated membrane trafficking. *Molecular Cell*, 7(2), 443–449. https://doi.org/10.1016/S1097-2765(01)00191-2

3. Franco, I., Gulluni, F., Campa, C. C., Costa, C., Margaria, J. P., Ciraolo, E., ... & Hirsch, E. (2014). PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. *Developmental Cell*, 28(6), 647–658. https://doi.org/10.1016/j.devcel.2014.02.004

4. Yoshioka, K., Yoshida, K., Cui, H., Wakayama, T., Takuwa, N., Okamoto, Y., ... &